EligibleTrials

Clinical trials recruiting for Clinical Stage IV Gastric Cancer AJCC v8

3
Recruiting trials
3
US states with sites
1
Countries
0%
Accept healthy volunteers

Phase breakdown

Phase 1 2Phase 2 1Not applicable 1

Drugs and treatments being studied

InterventionTrials
Cisplatin1
Cyclophosphamide1
Doxorubicin1
Fluorescein Sodium Injection1
Fluorouracil1
Irinotecan1
Leucovorin1
Mitomycin1
Neoantigen Peptide Vaccine1
Oxaliplatin1
Pembrolizumab1
Sargramostim1

Where trials are recruiting (top US states)

StateRecruiting trials
Florida3
California1
New York1

Top cities

Jacksonville, Florida 3Duarte, California 1Greenlawn, New York 1

Self-screener

Recruiting trials

Related conditions

Trials recruiting for Clinical Stage IV Gastric Cancer AJCC v8 often also study these conditions. Each links to its own recruiting-trial list.

Stage IVB Uterine Corpus Cancer AJCC v8 4Stage IVA Uterine Corpus Cancer AJCC v8 4Stage IV Hepatocellular Carcinoma AJCC v8 5Stage IV Colorectal Cancer AJCC v8 21Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8 3Metastatic Malignant Solid Neoplasm 21Metastatic Gastric Carcinoma 4Metastatic Colorectal Carcinoma 13Breast cancer 2239Anatomic Stage IV Breast Cancer AJCC v8 43

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Clinical Stage IV Gastric Cancer AJCC v8 trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.